AI Shifts Into the Next (Generative) Gear in Healthcare
Riepilogo
Artificial intelligence (AI) has been transforming health and medicine for several decades, whether through diagnostics, personalized medicine, data analytics or other innovations. The advent of generative AI is now reshaping drug discovery, diagnostics, clinical decisions and delivery of care. Traditional healthcare companies — whether healthcare providers, payers, technology partners or pharmaceutical companies — recognize generative AI’s potential. That potential can manifest in the form of faster drug discovery, more accurate diagnostic tools, improved clinical care and patient services, and so on. Each stakeholder is seeking ways to use the technology to their advantage. Medical professionals, patients and regulators are reacting to this new reality, pondering its implications — both promising and troubling — as well as yet-unanswered ethical questions. Health tech and Big Tech join forces on generative AI solutions. Today, traditional health IT and health-tech companies are partnering with tech giants such as Google, Amazon, Microsoft and Meta to bring their generative AI solutions to life. Leading health IT provider Epic’s partnership with Microsoft to integrate generative AI into its electronic health record (EHR) software is a notable example. The takeaway for both industry stakeholders and generative AI users is to watch investor actions. Sustained investor interest will drive the development of stronger, more effective use cases and lead to the emergence of numerous industry- specific generative AI applications in the years ahead. This trend mirrors the introduction of new technologies in previous decades. Startups set the stage for generative AI in healthcare. The generative AI market for healthcare is valued at more than $1 billion as of 2022, and it is projected to swell to almost $22 billion by 2032. Technology giants along with venture capitalists and private equity investors will play a significant role in that market as investors, partners and innovators. These investments stand to benefit tech startups like Abridge, which is working to integrate its generative AI medical note-taking tool with Epic, a move that promises to streamline clinical workflows. Similarly, startup company Basys.ai secured $2.4 million in seed funding to advance its prior authorization tool, which leverages generative AI and deep learning to expedite the insurance preapproval process for medical procedures. Doctors and patients must have a say in shaping generative AI’s role in clinical settings. For every claim of generative AI’s promise made by technology developers, there is often a fear of the unknown held by nearly everyone else, from medical professionals and patients to government officials. Medical professionals can play a crucial role in demystifying that unknown, especially for their patients. As the experts in care, they have earned patients’ trust through decades of experience and will be responsible for using generative AI in the clinical setting. Patients also must be part of the equation because, after all, it is their health that is at stake. Their fears, comfort levels, trust and consent are factors in determining whether and to what extent generative AI should be involved in their treatment.The post AI Shifts Into the Next (Generative) Gear in Healthcare first appeared on PYMNTS.com.
In "This Is How They Tell Me the World Ends," Nicole Perlroth, a former New York Times reporter, offers a detailed picture of how the zero-day exploit tra…
In "This Is How They Tell Me the World Ends," Nicole Perlroth, a former New York Times reporter, offers a detailed picture of how the zero-day exploit trade developed and affects critical infrastructure.
The post First Bitcoin ETF, Now Ethereum ETF, Whose Next SOL, XRP? appeared first on Coinpedia Fintech News On January 11, the U.S. Securities and Exchang…
First Bitcoin ETF, Now Ethereum ETF, Whose Next SOL, XRP?
Denaro elettronico · Blockchain · Servizi per le banche
Riepilogo
The post First Bitcoin ETF, Now Ethereum ETF, Whose Next SOL, XRP? appeared first on Coinpedia Fintech News On January 11, the U.S. Securities and Exchange Commission (SEC) approved the first Spot Bitcoin ETF. Four months later, the SEC approved another spot ETF, this time for Ethereum. This highlights the SEC’s evolving stance toward crypto adoption. Meanwhile, Crypto analysts at Standard Chartered weighed in on the potential ETF launch for other altcoins. Solana & XRP ETFs On The Line With Ethereum ETFs now on the market, attention is shifting towards other potential candidates for ETF approval. Geoffrey Kendrick, Head of Forex and Digital Assets Research at Standard Chartered Bank, suggests that Solana (SOL) and XRP ETFs could be approved as early as 2025. JUST IN: Standard Chartered analyst Geoffrey Kendrick said that cryptocurrency ETFs such as SOL and XRP may be approved in 2025, and the approval of the ETH ETF means that ETH and similar cryptocurrencies will not be classified as securities. pic.twitter.com/RECYwTnVRr— SolanaFloor (@SolanaFloor) May 24, 2024 Kendrick further highlights that the SEC’s treatment of Ethereum could set a precedent for other cryptocurrencies. He points out that if Ethereum is not considered a security, other coins with similar characteristics, such as Solana and XRP, might also evade this classification. Kendrick notes that the recent approval of Ethereum ETFs implies that ETH-like coins, which share similar technological foundations, may not be classified as securities by the SEC. The Future of Crypto ETFs Crypto analyst The Birb Nest observes that the narrative around a Solana ETF is gaining momentum on crypto Twitter and among media outlets. He suggests that while regulation will take time, the anticipation of a Solana ETF is growing. In the meantime, market participants are encouraged to drive a “full-blown meme mania” around Solana, similar to the hype seen with meme tokens like Dogecoin (DOGE) and Shiba Inu (SHIB). They will try to push the narrative that $SOL is another ETF.This will probably happen, but they definitely need more time and they need to introduce a legitimate #crypto regulatory framework.It will take time, but before they do that in the meantime we can unleash a… https://t.co/kHDZ1SMTwx— THE ₿IRB NEST (@TheBirbNest) May 24, 2024 BTC+ETH dominance will rise’ However, Kendrick predicts that Bitcoin and Ethereum will continue to dominate the market. He expects a strong inflow of investments into spot Bitcoin ETFs, projecting a potential BTC price target of $150,000 by the end of the year. This expected increase in Bitcoin and Ethereum dominance suggests that they will remain key players in the evolving landscape of cryptocurrency ETFs. As the SEC continues to pave the way for more crypto ETFs, the future looks promising for digital assets like Solana and XRP.
The post Ondo Hits New Highs Above $1; Will the Price Cross the Final Barrier to Reach $1.5? appeared first on Coinpedia Fintech News Bullish clouds are h…
Ondo Hits New Highs Above $1; Will the Price Cross the Final Barrier to Reach $1.5?
Denaro elettronico
Riepilogo
The post Ondo Hits New Highs Above $1; Will the Price Cross the Final Barrier to Reach $1.5? appeared first on Coinpedia Fintech News Bullish clouds are hovering over the crypto space as traders have become optimistic, followed by the approval of the spot Ethereum ETF. The traders became more sure of the next price action when the ETH price surged magnificently but fell short of a few dollars in reaching $4000. In the meantime, some altcoins have been maintaining a steep upswing while some are recording new ATH like Ondo, which has surged over 15% in the past 24 hours. After such a massive rally, many may expect a bearish pullback, but from a larger perspective, the token appears to be preparing for a fresh upswing, targeting another 40% upswing. The SEC approving the spot ETH ETF has catalysed the ongoing bullish upswing which has also led to the speculations of an altseason in a short while. ONDO price shot up by over 20% to reach $1.16 after consolidating below $1 for a few days. With this, the accumulated bullish momentum may assist a continued upswing for the rest of the month. As seen in the above chart, the ONDO price has been maintaining a strong bullish trend since the beginning. Meanwhile, the price is facing some hindrances in rising above the average bands of the rising parallel channel, but the bulls may lift the levels very soon. The RSI is in an incremental stage and may surge to reach within the overbought levels. This may offer the required push, but the price may refrain from reaching the upper resistance level of $1.5. Besides, the volume is also slowly piling up, which is offering the bulls the required momentum. Hence, the Ondo price is expected to maintain an elevated trend until the end of the month and discover new highs. Nevertheless, the price could rise and hit the upper resistance levels at $1.5 in the first few days of June, which will be a decisive phase for the token. If bulls hold their dominance, then a breakout could occur; otherwise, a rejection may cause the price to test lower support levels until it finds a strong base to trigger a rebound.